Biogen is buying anti-inflammatory drug startup RayThera for up to $1 billion
The deal adds multiple small-molecule anti-inflammatory drug candidates to Biogen's pipeline, with the lead asset set to begin human trials this summer
Biogen is buying anti-inflammatory drug startup RayThera for up to $1 billion
Overview
The deal adds multiple small-molecule anti-inflammatory drug candidates to Biogen's pipeline, with the lead asset set to begin human trials this summer
Source
Originally published at qz.com.
Related Articles
- Derm-Biome’s DB-006 Demonstrates Superior Efficacy in Preclinical Atopic Dermatitis Study: Reduces Itch, Inflammation, and IgE Levels, Outperforms Leading Topical Drugs
- PracticeLink Announces Spring 2026 First Practice Fund Scholarship Recipients
- New Digital Twins Study Finds Cannes Lions Is Marketing’s Most Polarizing Major Conference
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
